Table 1 The characteristics of included studies for analysis.
Author, year | Country | Mean age | Sample size | Dose (mg) | Duration of treatment (weeks) | Health condition | Intervention type | Sex | CRP change in intervention and placebo group a |
|---|---|---|---|---|---|---|---|---|---|
Mahdieh Abbasalizad Farhangi (2013) | Iran | 36 | 50 | 25,000 | 16 | Obese | Retinyl palmitate | F | 6.24 vs, 5.51 |
Shaikh M Ahmad (2020) | Bangladesh | 0.5 | 271 | 50,000 | 6 | Infants | Retinol | F/M | 0.38 vs, 0.41 |
S. A. Tanumihardjo (2020) | USA | 6 | 93 | 1333 | 12 | Low serum retinol | Retinol | F/M | 0.58 vs, 0.75 |
Charles B Stephensen (2002) | USA | 5 | 92 | 200,000 | 2 | Pneumonia | Retinol | F/M | 30 vs, 38.6 |
Francisco J. Rosales (2002) (a) | USA | 8.5 | 88 | 200,000 | 2 | Pneumonia | Retinol | F/M | 22.03 vs, 19.37 |
Francisco J. Rosales (2002) (b) | USA | 8.5 | 108 | 200,000 | 2 | Pneumonia | Retinol | F/M | 17.83 vs, 16.28 |
Trevino A Pakasi (2010) (a) | Indonesia | 35 | 136 | 5000 | 8 | TB | Retinol | F/M | 4 vs, 6.4 |
Trevino A Pakasi (2010) (b) | Indonesia | 35 | 136 | 5000 | 8 | TB | Retinol | F/M | 1.5 vs, 1.7 |
Trevino A Pakasi (2010) (c) | Indonesia | 35 | 119 | 5000 | 8 | TB | Retinol | F/M | 4.2 vs, 6.4 |
Trevino A Pakasi (2010) (d) | Indonesia | 35 | 119 | 5000 | 8 | TB | Retinol | F/M | 1.1 vs, 1.3 |
Shaikh M Ahmad (2008) | Bangladesh | 23.9 | 36 | 200,000 | 1 | Low serum retinol | Retinol | M | 1.27 vs, 0.75 |
Ph Donnen (a) (2001) | Brussels | 3 | 542 | 200,000 | 1 | During infection | Retinyl palmitate | F/M | 34.6 vs, 31.9 |
Ph Donnen (b) (2001) | Brussels | 3 | 540 | 5000 | 1 | During infection | Retinyl palmitate | F/M | 32.2 vs, 31.9 |
Sima Jafarirad (2013) | Iran | 32.5 | 35 | 200,000 | 24 | MS | Retinyl palmitate | F/M | 2.88 vs, 1.58 |
